Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F19%3A00108620" target="_blank" >RIV/00216224:14740/19:00108620 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/19:00072283
Result on the web
<a href="http://dx.doi.org/10.1093/annonc/mdz413.102" target="_blank" >http://dx.doi.org/10.1093/annonc/mdz413.102</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/annonc/mdz413.102" target="_blank" >10.1093/annonc/mdz413.102</a>
Alternative languages
Result language
angličtina
Original language name
Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours
Original language description
The necessary condition for the application of precision oncology approach into the routine is a detailed molecular characterization of the tumour. In our study, we explored clinical applicability of both whole exome sequencing (WES) and FoundationOne Heme (F1Heme) panel (Foundation Medicine, Inc., MA, USA) as comprehensive genomic profiling tools in a cohort of 35 children with difficult-to-treat solid tumours.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV16-33209A" target="_blank" >NV16-33209A: Genome-wide expression profiling and mutation analysis as the diagnostic basis for personalized pediatric cancer treatment plans: a feasibility study</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů